Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_3
5
100%

Phase Distribution

0

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
5(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 35 (100.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00338312
completedphase_3

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331214
completedphase_3

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331123
completedphase_3

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

NCT00349791
completedphase_3

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

NCT00467259

Clinical Trials (5)

Showing 5 of 5 trials
NCT00338312Phase 3

Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

Completed
NCT00331214Phase 3

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

Completed
NCT00331123Phase 3

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

Completed
NCT00349791Phase 3

Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido

Completed
NCT00467259Phase 3

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5